Efficacy of "Integrated Social Cognitive and Behavioral Skills Therapy" (ISST) in Improving Functional Outcome in Schizophrenia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 177
- 试验地点
- 7
- 主要终点
- All Cause Discontinuation
研究概览
简要总结
The ISST study investigates whether integrated social cognitive remediation and social behavioral skills therapy is more efficacious in improving functional outcome and treatment adherence than an active control treatment comprising drill-and-practice oriented neurocognitive remediation.
详细描述
Deficits in social functioning are a defining, very burdening feature of schizophrenia precluding patients from participating in a satisfying life. Traditional drug and psychosocial therapy and available specific treatment strategies that directly target single key determinants of functional outcome like neurocognition, social cognition, and social behavioral skills have produced only moderate effects leaving an urgent need for further optimization. The present trial aims to more efficaciously improve functional outcome by integrating social behavioral and social cognitive treatment strategies. Six months of "Integrated Social Cognitive and Behavioral Skills Therapy (ISST)" will be compared with "Neurocognitive Remediation Therapy (NCRT)" as active control condition in a randomized multicenter clinical trial using a two group pre-post design with 2x90 patients in the remitted early phase of schizophrenia. Beyond "all-cause-discontinuation" as common primary outcome of all clinical trials of the ESPRIT-consortium, measures of functional outcome and subjective quality of life, patient experience as well as neurocognitive, social-cognitive and social behavioral measures will be assessed at baseline (V0), after completion of treatment (V6), and after 6 months follow-up (V12). ISST is expected to reduce the one-year discontinuation rate by 20% compared with NCRT, and to be superior in functional outcome measures by an effect size of at least d=0.42.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •DSM-IV-TR diagnosis of schizophrenia (295.10-30, 295.90)
- •PANSS at baseline: total score ≤ 75
- •Proficiency in German language.
排除标准
- •Lack of accountability
- •Positive urine drug-screening for illicit drugs at screening (except cannabinoids and benzodiazepines)
- •Serious suicidal risk at screening visit
- •Other relevant axis 1-diagnoses according to diagnostic interview (MINI);
- •Other relevant neurological or somatic disorders
- •Verbal IQ<80 (MWT-B)
结局指标
主要结局
All Cause Discontinuation
时间窗: 6 months, 12 months
All Cause Discontinuation is defined as 1) not keeping appointments to treatment or diagnostic sessions as scheduled for more than 6 weeks and/or (2) not being traceable despite extensive efforts by the intervention team to reengage the patient throughout the entire intended treatment period and/or (3) withdrawal of consent by the patient (4) rater induced discontinuation of the study treatment (eg. for safety criteria) (5) not taking psychotropic drugs as prescribed for more than 14 consecutive days and/or (6) relevant worsening of symptoms.
次要结局
- WHOQUOL-Bref (Quality of Life)(6 months, 12 months)
- Treatment Adherence 2(6 months, 12 months)
- Treatment Adherence 1(6 months, 12 months)
- Neurocognitive Performance (working memory)(6 months, 12 months)
- Neurocognitive Performance (processing speed 1)(6 months, 12 months)
- Psychosocial Functioning 2(6 months, 12 months)
- Socialcognitive Performance (affect recognition)(6 months, 12 months)
- Psychopathology/Symptoms 1(6 months, 12 months)
- Neurocognitive Performance (processing speed 2)(6 months, 12 months)
- Treatment Adherence 3(6 months, 12 months)
- Psychosocial Functioning 1(6 months, 12 months)
- Neurocognitive Performance (verbal memory)(6 months, 12 months)
- Socialcognitive Performance (theory of mind)(6 months, 12 months)
- Psychopathology/Symptoms 2(6 months, 12 months)
- Psychopathology/Symptoms 3(6 months, 12 months)
- Severe symptom worsening(Assessed every 4-6 weeks from date of randomization until 1 year or until discontinuation (whatever came first))
- Suicidality(Assessed every 4-6 weeks from date of randomization until 1 year or until discontinuation (whatever came first))
研究者
Wolfgang Wölwer
Prof. Dr. phil.
Heinrich-Heine University, Duesseldorf
